GSK Signs a License Agreement with Sosei Heptares Targeting Immune Disorders of the Digestive System

Shots:

• Sosei Heptares to receive $44M as upfront, near-term development milestones, and funding and is eligible to receive $437M as development, regulatory, and commercialization along with royalties on sales of products resulting from the collaboration
• GSK gets the global rights to a Sosie Heptares’ portfolio of GPR35 agonists, developed utilizing StaR technology & SBDD platform. The licensed portfolio includes an advanced lead preclinical compound as well as multiple differentiated back-up compounds
• The companies collaborated on research and early preclinical development while GSK will lead clinical development, manufacturing, and commercialization

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: McMaster Optimal Aging Portal